Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis

AIDS

Volumn 15, Issue 3, 2001, Pages 347-355

  Detels, Roger ^a,e   Tarwater, Patrick ^b   Phair, John P ^c   Margolick, Joseph ^b   Riddler, Sharon A ^d   Muñoz, Alvaro ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE

Author keywords

AIDS; Cohort; HAART; HIV; Opportunistic infections; Potent antiretroviral therapy

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEROCONVERSION; SUPERINFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; COHORT STUDIES; DISEASE PROGRESSION; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMOCYSTIS INFECTIONS; PREVALENCE; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 0035895657     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102160-00008     Document Type: Article

References (24)

1. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
2. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
5. AIDS across Europe, 1994-98: The EuroSIDA study
6. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society - USA panel
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Decline in deaths from AIDS due to new antiretrovirals
9. Update: Trends in AIDS incidence, deaths, and prevalence - United States, 1996
10. Use of protease inhibitors among persons with AIDS in Los Angeles County
11. Declining AIDS mortality in New York City
12. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
13. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1 infected individuals
14. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy
15. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants
16. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study
17. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study
18. Using multiple decrement models to estimate risk and morbidity from specific AIDS illnesses
19. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression
20. Methods for analysis of the occurrence of abscess in patients with pancreatitis
21. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
22. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
23. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EurosSIDA Study
24. The two sample problem with censored data